<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="658">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992523</url>
  </required_header>
  <id_info>
    <org_study_id>MOJITO Study</org_study_id>
    <nct_id>NCT01992523</nct_id>
  </id_info>
  <brief_title>Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )</brief_title>
  <official_title>Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Antoniucci</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>A.R. CARD Onlus Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Careggi Hospital</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the Mashed Or Just Integral pill of TicagrelOr (MOJITO) study is to evaluate the
      superiority of Ticagrelor 180 mg LD mashed pill versus Ticagrelor 180 mg LD integral pill
      both orally administrated in decreasing residual platelet reactivity 1 hour after the
      administration among 70 patients with STEMI (ST segment elevation myocardial infarction)
      undergoing PPCI (primary percutaneous coronary intervention) with bivalirudin monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Residual Platelet Reactivity</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>residual platelet reactivity by Platelet Reactivity Units (PRU) VerifyNow 1 hour after ticagrelor LD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Residual Platelet Reactivity</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percent of patients with a high residual platelet reactivity (PRU &gt; 208) 1 hour after ticagrelor LD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of participants with Major, minor, minimal bleeding (TIMI criteria) events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea and/or Symptomatic Bradycardia</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of participants with Occurrence of dyspnoea and/or symptomatic bradycardia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Adverse Reaction to Antiplatelet Agent</condition>
  <arm_group>
    <arm_group_label>Ticagrelor mashed pills</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor loading dose (LD) 180 mg as mashed pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor integral pills</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor loading dose (LD) 180 mg as integral pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor mashed pills</intervention_name>
    <description>The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.</description>
    <arm_group_label>Ticagrelor mashed pills</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor integral pills</intervention_name>
    <description>The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).</description>
    <arm_group_label>Ticagrelor integral pills</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting within 12 hours from the onset of symptoms with STEMI

          -  Informed, written consent

        Exclusion Criteria:

          -  Age &lt; 18 years or Age &gt; 75 years

          -  Active bleeding; bleeding diathesis; coagulopathy

          -  Increased risk of bradycardiac events

          -  History of gastrointestinal or genitourinary bleeding &lt;2 months

          -  Major surgery in the last 6 weeks

          -  History of intracranial bleeding or structural abnormalities

          -  Suspected aortic dissection

          -  Any other condition that may put the patient at risk or influence study results or
             investigator's opinion (severe hemodynamic instability, known malignancies or other
             comorbid conditions with life expectancy &lt;1 year)

          -  Administration in the week before the index event of clopidogrel, ticlopidine,
             prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or
             fondaparinux .

          -  Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers,
             CYP3A with narrow therapeutic windows

          -  Known relevant hematological deviations: Hb &lt;10 g/dl, Thrombi. &lt;100x10^9/l

          -  Use of coumadin derivatives within the last 7 days

          -  Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine

          -  Known severe liver disease, severe renal failure

          -  Known allergy to the study medications

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Parodi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Careggi Hospital, Division of Invasive Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Antoniucci, MD</last_name>
    <role>Study Director</role>
    <affiliation>Careggi Hospital, Division of Invasive Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 4, 2015</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <firstreceived_results_date>September 25, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Careggi Hospital</investigator_affiliation>
    <investigator_full_name>David Antoniucci</investigator_full_name>
    <investigator_title>Director, Division of Invasive Cardiology</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>antiplatelet</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor Mashed Pills</title>
          <description>Ticagrelor loading dose (LD) 180 mg as mashed pills
Ticagrelor mashed pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.</description>
        </group>
        <group group_id="P2">
          <title>Ticagrelor Integral Pills</title>
          <description>Ticagrelor loading dose (LD) 180 mg as integral pills
Ticagrelor integral pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor Mashed Pills</title>
          <description>Ticagrelor loading dose (LD) 180 mg as mashed pills
Ticagrelor mashed pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.</description>
        </group>
        <group group_id="B2">
          <title>Ticagrelor Integral Pills</title>
          <description>Ticagrelor loading dose (LD) 180 mg as integral pills
Ticagrelor integral pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="64" spread="13"/>
                <measurement group_id="B2" value="61" spread="14"/>
                <measurement group_id="B3" value="62" spread="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Greece</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Italy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="52"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Residual Platelet Reactivity</title>
        <description>residual platelet reactivity by Platelet Reactivity Units (PRU) VerifyNow 1 hour after ticagrelor LD.</description>
        <time_frame>1 hour</time_frame>
        <safety_issue>No</safety_issue>
        <population>Continuous data were expressed as mean ± standard deviation or medians (quartiles) as appropriate, and categorical data as proportions (%). A P value &lt; .05 was considered statistically significant. All tests were two-sided.</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor Mashed Pills</title>
          </group>
          <group group_id="O2">
            <title>Ticagrelor Integral Pills</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Residual Platelet Reactivity</title>
            <description>residual platelet reactivity by Platelet Reactivity Units (PRU) VerifyNow 1 hour after ticagrelor LD.</description>
            <units>PRU (P2Y12 reaction units)</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="168" lower_limit="61" upper_limit="251"/>
                  <measurement group_id="O2" value="252" lower_limit="167" upper_limit="301"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Continuous data were expressed as mean ± standard deviation or medians (quartiles) as appropriate, and categorical data as proportions (%). Data were compared by means of the chi-2 test or Fisher exact test for categorical variables and unpaired t test or Mann-Whitney U-test for continuous variables, as appropriate. A P value &lt; .05 was considered statistically significant. All tests were two-sided.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.006</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Residual Platelet Reactivity</title>
        <description>The percent of patients with a high residual platelet reactivity (PRU &gt; 208) 1 hour after ticagrelor LD.</description>
        <time_frame>1 hour</time_frame>
        <safety_issue>No</safety_issue>
        <population>Categorical data were expressed as proportions (%)</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor Mashed Pills</title>
            <description>Ticagrelor loading dose (LD) 180 mg as mashed pills
Ticagrelor mashed pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor Integral Pills</title>
            <description>Ticagrelor loading dose (LD) 180 mg as integral pills
Ticagrelor integral pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>High Residual Platelet Reactivity</title>
            <description>The percent of patients with a high residual platelet reactivity (PRU &gt; 208) 1 hour after ticagrelor LD.</description>
            <units>percentage of partecipants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Events</title>
        <description>Percentage of participants with Major, minor, minimal bleeding (TIMI criteria) events</description>
        <time_frame>48 hours</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor Mashed Pills</title>
            <description>Ticagrelor loading dose (LD) 180 mg as mashed pills
Ticagrelor mashed pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor Integral Pills</title>
            <description>Ticagrelor loading dose (LD) 180 mg as integral pills
Ticagrelor integral pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Bleeding Events</title>
            <description>Percentage of participants with Major, minor, minimal bleeding (TIMI criteria) events</description>
            <units>percentage of partecipants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.4"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnoea and/or Symptomatic Bradycardia</title>
        <description>Percentage of participants with Occurrence of dyspnoea and/or symptomatic bradycardia</description>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Continuous data were expressed as mean ± standard deviation or medians (quartiles) as appropriate, and categorical data as proportions (%)</population>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor Mashed Pills</title>
            <description>Ticagrelor loading dose (LD) 180 mg as mashed pills
Ticagrelor mashed pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor Integral Pills</title>
            <description>Ticagrelor loading dose (LD) 180 mg as integral pills
Ticagrelor integral pills: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Dyspnoea and/or Symptomatic Bradycardia</title>
            <description>Percentage of participants with Occurrence of dyspnoea and/or symptomatic bradycardia</description>
            <units>percentage of partecipants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Intra-hospital events</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor Mashed Group</title>
          <description>patients taking orally 180 mg ticagrelor mashed tablets</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor Integral Group</title>
          <description>patients taking orally 180 mg ticagrelor integral tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>Cardiovascular and non cardiovascular death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Re-infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Major bleeding (TIMI criteria)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular pauses &gt;= 3 sec</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Serum creatinine increase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>TIMI minor bleeding (TIMI criteria)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guido Parodi</name_or_title>
      <organization>Careggi Hospital</organization>
      <phone>00390557947732</phone>
      <email>parodiguido@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
